

MHRA
10 South Colonnade
Canary Wharf
London
E14 4PU
United Kingdom

[gov.uk/mhra](https://www.gov.uk/mhra)

Decision Cover Letter

Decision of the licensing authority to:

accept change(s) to the agreed paediatric investigation plan (MHRA-100332-PIP01-21) and to the deferral

MHRA-100332-PIP01-21-M01

Scope of the Application

Active Substance(s)

sotatercept

Condition(s)

Treatment of pulmonary arterial hypertension

Pharmaceutical Form(s)

Powder for solution for injection

Route(s) of Administration

SUBCUTANEOUS USE

Name / Corporate name of the PIP applicant

Merck Sharp & Dohme (UK) Limited

Basis for the Decision

Pursuant to the Human Medicines Regulations 2012, Merck Sharp & Dohme (UK) Limited submitted to the licensing authority on 17/11/2022 22:33 GMT an application for a Modification

The procedure started on 03/04/2023 11:13 BST

1. The licensing authority, having assessed the application in accordance with the Human Medicines Regulations 2012, decides, as set out in the appended summary report:

to accept change(s) to the agreed paediatric investigation plan and to the deferral

2. The measures and timelines of the paediatric investigation plan are set out in the Annex I.

This decision is forwarded to the applicant, together with its annex and appendix.

MHRA
10 South Colonnade
Canary Wharf
London
E14 4PU
United Kingdom

gov.uk/mhra

Final Decision Letter

MHRA-100332-PIP01-21-M01

Of 24/05/2023 20:58 BST

On the adopted decision for sotatercept (MHRA-100332-PIP01-21-M01) in accordance with the Human Medicines Regulations 2012.

The licensing authority, in accordance with the Human Medicines Regulations 2012, has adopted this decision:

Agreement on modification of a paediatric investigation plan (including modification of a waiver or deferral included in that paediatric investigation plan)

This decision applies to a Modification for sotatercept, Powder for solution for injection , SUBCUTANEOUS USE .

This decision is addressed to Merck Sharp & Dohme (UK) Limited, 120 Moorgate, London, UNITED KINGDOM, EC2M 6UR

ANNEX I

1. Waiver

1.1 Condition:

Treatment of pulmonary arterial hypertension The waiver applies / applied to: Paediatric Subset(s): The paediatric population from birth to less than 1 year of age Pharmaceutical form(s): Powder for solution for injection Route(s) of administration: Subcutaneous use Reason for granting waiver: on the grounds that the specific medicinal product is likely to be unsafe.

2. Paediatric Investigation Plan:

2.1 Condition(s):

Treatment of pulmonary arterial hypertension (PAH)

2.2 Indication(s) targeted by the PIP:

Treatment of PAH, World Health Organisation (WHO) Group 1, to improve exercise tolerance and functional class.

2.3 Subset(s) of the paediatric population concerned by the paediatric development:

The paediatric population from 1 year to less than 18 years of age

2.4 Pharmaceutical Form(s):

Powder for solution for injection

2.5 Studies:

Study Type	Number of Studies	Study Description
Quality Measures	1	Study 1 Development of an age-appropriate dosage form.
Non-Clinical Studies	0	Not applicable.
Clinical Studies	1	Study 2 Open label, 24-week study to assess pharmacokinetics (PK), safety and pharmacodynamic effects of sotatercept as add-on therapy to standard-of-care in children from 1 year to less than 18 years of age with pulmonary arterial hypertension (PAH).
Extrapolation, Modeling & Simulation Studies	2	Study 3 Population pharmacokinetic/ pharmacodynamic analysis to support the extrapolation of efficacy of sotatercept in the treatment of PAH in children from 1 year to less than 18 years of age. Study 4 Analysis of existing inhouse and literature data to support extrapolation of efficacy of sotatercept in the treatment of PAH in children from 1 year to less than 18 years of age.
Other Studies	0	Not applicable.
Other Measures	0	Not applicable.

3. Follow-up, completion and deferral of a PIP:

Concerns on potential long term safety and efficacy issues in relation to paediatric use:	Yes
Date of completion of the paediatric investigation plan:	30/04/2029

Deferral of one or more studies contained in the paediatric investigation plan:	Yes
--	-----